| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aaacf277d1ca555b6a99ad72dec179b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b668fc9d25b132a469814bfe01025fef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2507a390db4f7f5f5f450293d8b06f03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e1b17d3a60c233cf07df72335ab0c9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate |
2004-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04f0660feb631c38ff3b51396d8afe72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b55b378ec219697a3ba81541f00f7082
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_564554f01f26b70ebad6baa1d5395e43 |
| publicationDate |
2005-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2005009414-A1 |
| titleOfInvention |
Sutained release formulation for venlafaxine hydrochloride |
| abstract |
The invention provides a sustained release composition that; 1. Is free of initially increased drug delivery that occurs in sustained release systems containing the water soluble drug venlafaxine HCl, known as burst phenomenon, by using a functional core partially or totally coated by a functional coating layer or film. 2. Delivers the drug substance within 24 hours and is therefore suitable for once daily administration of the said drug substance. 3. Exhibits linearity between the strength dosage form and the total mass of the dosage form, by proportional increase of the amounts of the drug substance and the excipients in the formulation. 4. Is possible to be divided in smaller doses, without affecting the release of the drug substance. The invention provides a sustained release capsule formulation containing an appropriate number of functional complex mini tablets comprising of: I . A functional core comprising the active ingredient, especially the water-soluble drug Venlafaxine HCl and appropriate excipients. 2. A functional coating layer or film that reduces the initial surface of the core that is available for the release of the water-soluble drug Venlafaxine HC1t phenomenon |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8062666-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005048979-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005048979-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8557282-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2010158-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007112574-A1 |
| priorityDate |
2003-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |